Posted in: information

Dunen medical completed a new round of financing of nearly 100 million yuan, led by CICC capital

On April 24, 2022, Hangzhou dunen medical laboratory Co., Ltd. (hereinafter referred to as”dunen medicine”)Announced the completion of a new round of financing, chenzhijun, founder of dunen medicine, tujixian, deputy general manager of CICC Capital Operation Co., Ltd., shaoxiangrong, deputy secretary of Zhejiang Tsinghua Yangtze River Delta Research Institute, Professor chenshuqing, School of pharmacy, Zhejiang University, and other leaders attended the financing signing ceremony.

This round of financing is nearly 100 million yuan, led by CICC capital and followed by other well-known domestic funds.After the completion of this round of strategic financing, dunen medicine will make every effort to build an ecosystem around the pharmaceutical care industry, including the construction and operation of clinical precision medication platforms, the research and development of products related to drug genetic testing and therapeutic drug monitoring, the establishment of precision medication databases, the development of medication guidance software supported by big data, the development of AI pharmacists, and clinical services for innovative drug research and development.

Dunen medicine, founded in 2017, is a domestic high-tech enterprise carrying out clinical precision medication guidance services. It is the landing unit of the”precision Medication Research Center” of Hangzhou branch of Zhejiang Tsinghua Yangtze River Delta Research Institute. The company’s business mainly focuses on precision medication services, a market with great potential. Dunen medicine has a strong R & D team, of which talents with master’s degree or above account for more than one third of the team. The company will always be committed to providing global medical experts and patients with better and more reliable precision medication solutions, and make unremitting efforts to promote the development of human health.

Chenzhijun, the founder of dunen medicine, said:after previous hard work, dunen medicine has become an innovative biomedical enterprise with great vitality and great development potential. Thank you very much for the recognition of dunen medicine by the capital market. This financing has planted wings for the rapid development of dunen medicine. We will take this cooperation as an opportunity to be down-to-earth and pragmatic. We are confident to make the enterprise bigger and stronger and build a leading enterprise in pharmaceutical care.

Shaoxiangrong, deputy secretary of Zhejiang Tsinghua Yangtze River Delta Research Institute, said:dunen medicine has a young and energetic team, and we very much recognize its layout in the pharmaceutical care industry. It is a biomedical enterprise that the Institute focuses on cultivating and building. Zhejiang Tsinghua Yangtze River Delta Research Institute will continue to provide talent introduction, talent training, scientific and technological innovation and other services for dunen medicine, hoping that dunen can become a unicorn enterprise in this segment.

Professor chenshuqing, School of pharmacy, Zhejiang University, said:irrational drug use is one of the great challenges facing medicine, which leads to poor clinical drug treatment effect, serious adverse reactions and even death of a large number of patients. It is hoped that dunen medicine, in promoting the development of clinical pharmaceutical care, will take patients as the center, comprehensively improve the level of pharmaceutical care, and play an important role in promoting the high-quality development of precision pharmacy in the future.